Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323777
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | 13,111 | 10,735 | 24,300 | 19,403 |
| Gross profit | 18,902 | 12,503 | 35,339 | 21,474 |
| Operating expenses: | ||||
| Research and development | 10,240 | 8,873 | 20,596 | 16,463 |
| Sales and marketing | 24,640 | 15,623 | 45,375 | 29,025 |
| General and administrative | 9,600 | 7,879 | 19,217 | 14,500 |
| Total operating expenses | 44,480 | 32,375 | 85,188 | 59,988 |
| Loss from operations | (25,578) | (19,872) | (49,849) | (38,514) |
Item 1. Financial Statements.
FAQ
- What is Beta Bionics's R&D?
- Beta Bionics (BBNX) reported R&D of $10.24M in Q2 2026.
- How has Beta Bionics's R&D changed year-over-year?
- Beta Bionics's R&D increased by 15.4% year-over-year, from $8.87M to $10.24M.
- What is the long-term trend for Beta Bionics's R&D?
- Over 2 years (2023 to 2025), Beta Bionics's R&D has grown at a 39.2% compound annual growth rate (CAGR), from $17.94M to $34.79M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Beta Bionics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude